- IXICO, together with its alliance partner, VirtualScopics, has been awarded contracts with two top 15 pharmaceutical companies, one in metastatic solid tumours and one in a rare neurodegenerative disease.

IXICO's TrialTracker digital platform will be deployed in both studies to collect and manage imaging data and in the neurodegeneration study, IXICO's Assessa digital technology will be used to analyse MRI data collected from patients.

The metastatic solid tumour study will make use of VirtualScopics extensive expertise applying FDG-PET (Fludeoxyglucose PET) to measuring disease progression in oncology and will involve working with imaging centres across North America and Europe. The study is expected to complete in June 2017.

The neurodegeneration study will make use of IXICO's expertise in structural MRI and will involve IXICO working with key opinion leaders across specialist imaging centres throughout North America.

As part of this contract, IXICO's Assessa® medical device will utilise its proprietary LEAP methodology to quantify disease pathology in brain regions that are particularly relevant to measuring disease progression and will be applied to MRI data collected from subjects enrolled in the study. The study is expected to complete in January 2018.

IXICO chief executive Professor Derek Hill said: "Our alliance with VirtualScopics continues to be valued by our pharmaceutical partners as we support their clinical trials on a global basis, as evidenced by these two new contract wins.

"Our TrialTracker digital platform provides customers with digital technology combined with operational effectiveness. Furthermore, our involvement with the neurodegenerative disease study demonstrates our ability to broaden our therapeutic expertise and validates the importance of IXICO's technology across a range of brain diseases."

At 8:06am: [LON:IXI] IXICO plc share price was 0p at 22.5p

Story provided by